By Oliver Haill
Date: Thursday 26 Jan 2017
LONDON (ShareCast) - (ShareCast News) - Johnson & Johnson, the world's biggest healthcare company, has agreed to acquire Europe's biggest biotech company, Switzerland-based Actelion, for $30bn in cash.
The $280-per-share deal involved spinning off Actelion's R&D unit into a standalone company that would be listed in Switzerland and where Johnson & Johnson will initially hold a 16% stake.
US-based J&J initially abandoned talks due to a disagreement over the price, before exclusive talks were restarted a week later.
"We believe this transaction offers compelling value to both Johnson & Johnson and Actelion shareholders," said J&J chairman and CEO Alex Gorsky.
"We expect to leverage our established global presence and commercial strength to accelerate growth and patient access to these important therapies. Further, we believe R&D NewCo will be strongly positioned to continue Actelion's legacy of innovation and look forward to collaborating on the development of cutting-edge new therapies."
Actelion counterpart Jean Pierre Garnier said: "I'm very proud that we have created such a unique value proposition through this structured transaction. Actelion's shareholders can monetize their holdings in Actelion at a highly attractive cash price of $280 per share, while at the same time retaining a significant stake in the future potential upside of Actelion's earlier stage pipeline, through their ownership of R&D NewCo."
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 146.67 |
Change Today | $ 1.39 |
% Change | 0.96 % |
52 Week High | $174.48 |
52 Week Low | $144.38 |
Volume | 14,621,203 |
Shares Issued | 2,407.08m |
Market Cap | $353,046m |
RiskGrade | 87 |
Strong Buy | 5 |
Buy | 6 |
Neutral | 11 |
Sell | 0 |
Strong Sell | 0 |
Total | 22 |
Time | Volume / Share Price |
15:59 | 100 @ $146.85 |
15:59 | 100 @ $146.86 |
15:59 | 100 @ $146.86 |
15:59 | 100 @ $146.87 |
15:59 | 250 @ $146.87 |
You are here: research